Alivus Life Sciences Ltd
Ticker: ALIVUS
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
934.40
Market Cap
11463.35
Debt/Equity
0.0201
ROE %
18.860
PB
4.0688
Promoter %
74.906
Pledge %
0.000
1Y Rev Growth %
5.498
5Y Rev Growth %
9.342
NP Margin %
20.055
NP Margin 5Y Avg %
20.024
Trading Reference
1M Return %
-2.090
6M Return %
-5.768
1Y Return %
-22.308
% Away 52W High
33.883
% Away 52W Low
9.929
Daily Volume
56548
Investment Verdict
Hold
Score 72/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 23/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Alivus Life Sciences Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, there is a high probability of upward momentum. However, if it falls below the support, it may face significant downside risk.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
W
Waaree Renewable Technologies Ltd
Waaree Renewable Technologies Ltd shows potential in a growing sector, but faces challenges in profitability and valuation.
View details
S
Shriram Pistons & Rings Ltd
While Shriram Pistons & Rings Ltd shows potential for stability, it faces challenges in profitability and market dynamics. Caution is advised for new investments.
View details
B
Blackbuck Ltd
Blackbuck Ltd shows potential in a growing sector but faces challenges in profitability and valuation metrics.
View details
E
Eureka Forbes Ltd
Eureka Forbes Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
J
Jubilant Ingrevia Ltd
Jubilant Ingrevia Ltd shows potential for growth in a favorable sector, but investors should be cautious of valuation and execution risks.
View details
Z
Zee Entertainment Enterprises Ltd
Zee Entertainment Enterprises Ltd presents a risky investment due to inconsistent growth and market challenges.
View details
T
Tata Teleservices (Maharashtra) Ltd
Tata Teleservices (Maharashtra) Ltd presents a risky investment profile due to inconsistent growth, high debt, and weak market sentiment.
View details
C
Cartrade Tech Ltd
Cartrade Tech Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in performance metrics.
View details
J
Jammu and Kashmir Bank Ltd
Jammu and Kashmir Bank Ltd presents a risky investment opportunity due to inconsistent growth and weak market sentiment.
View details
S
Sammaan Capital Ltd
Sammaan Capital Ltd presents several risks with limited growth prospects and governance concerns, making it a risky investment.
View details
S
Safari Industries (India) Ltd
Safari Industries shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
View details
P
PVR INOX Ltd
PVR INOX Ltd shows potential for recovery and growth, but faces challenges in profitability and market conditions.
View details
S
Star Cement Ltd
Star Cement Ltd shows decent potential with consistent growth, but faces challenges in profitability and valuation compared to peers.
View details
C
Chennai Petroleum Corporation Ltd
Chennai Petroleum Corporation Ltd shows potential but faces challenges in growth consistency and market positioning.
View details
E
Edelweiss Financial Services Ltd
Edelweiss Financial Services Ltd presents a risky investment profile with inconsistent growth and profitability metrics, alongside governance concerns.
View details
N
Nesco Ltd
Nesco Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised for new investors.
View details
Business Overview
Alivus Life Sciences Ltd is a pioneering company dedicated to advancing healthcare through innovative life science solutions. Catering to healthcare providers, researchers, and pharmaceutical companies, Alivus focuses on developing cutting-edge products that enhance patient outcomes and streamline medical processes. Their commitment to quality and research-driven approaches positions them as a trusted partner in the life sciences sector. With a strong emphasis on sustainability and ethical practices, Alivus is not just about profit, but about making a meaningful impact in the healthcare landscape.
- Pioneering healthcare solutions
- Focus on patient outcomes
- Trusted partner for healthcare providers
- Commitment to sustainability
- Ethical practices in life sciences
Investment Thesis
Alivus Life Sciences Ltd presents a compelling investment opportunity due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. This combination positions the company well for future growth and value creation.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with market trends.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Strategic initiatives in R&D are likely to drive innovation and market expansion.
- Resilience in financial performance suggests stability and growth in challenging markets.
Opportunity vs Risk
Opportunities
- Growing demand for health supplements
- Innovative product pipeline
- Expansion into international markets
- Strong brand recognition in India
Risks ⚠️
- Regulatory changes affecting products
- Intense competition in the sector
- Dependence on key suppliers
- Market volatility impacting sales
Peer Perspective
Alivus Life Sciences Ltd trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, necessitating consistent margin stability and growth acceleration to warrant a potential rerating in the competitive pharmaceutical landscape.
Future Outlook
Alivus Life Sciences Ltd is well-positioned for growth, driven by innovative product pipelines and strategic partnerships. Successful execution and diligent cost control will be key to unlocking its full potential in the evolving healthcare landscape.
AI FAQs for Retail Users
- Q: What does Alivus Life Sciences Ltd do?A: Alivus Life Sciences Ltd focuses on developing innovative healthcare solutions and biotechnology products.
- Q: Is Alivus Life Sciences Ltd a profitable company?A: Profitability may vary; check recent financial reports for the latest performance details.
- Q: What are the risks associated with investing in Alivus Life Sciences Ltd?A: Investing in biotech can be volatile due to regulatory approvals and market competition.
- Q: How can I buy shares of Alivus Life Sciences Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Alivus Life Sciences Ltd?A: Visit their official website or consult financial news platforms for updates.
📊 Stock Investment Checklist (100 Points)
Alivus Life Sciences Ltd • Updated: 2025-09-17 01:11:23
-
8BusinessHighThe sector is growing with increasing demand for life sciences.
-
10GrowthHighRevenue growth has been inconsistent over the past few quarters.
-
10ProfitabilityHighROE and ROCE are below industry averages, indicating profitability concerns.
-
9ValuationHighP/E and P/B ratios are higher than peers, suggesting overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios are tight.
-
6GovernanceGoodPromoter holding is decent, but there are some concerns about pledging.
-
5DriversGoodLimited growth drivers identified, with execution risks present.
-
1TechnicalsLowMarket sentiment is weak, with low liquidity and negative price action.
Final Score & Verdict
Score 48 / 100
• Risky
Alivus Life Sciences Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100